Clinical trial Recruiting at 1 site Interventional Ages 18 and up

PAW-hydrogel to help chronic wounds like diabetic foot and leg ulcers heal faster

Official title: Efficacy and Safety of a Carbopol® 940 Hydrogel Functionalized With Plasma-Activated Water (PAW) in the Treatment of Chronic Wounds: A Randomized Controlled Trial

Run by National Institute of Nuclear Research - Mexico · NCT07541196 · Data updated 2026-11-12

This trial will test whether a plasma-activated water–infused Carbopol® 940 hydrogel helps adults with long-standing wounds (diabetic foot, pressure, venous, arterial, or dehiscent ulcers) heal faster and have less bacteria compared with standard advanced wound care.

More Venous Leg Ulcer trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorNational Institute of Nuclear Research - Mexico
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Ocoyoacac, State of Mexico)
StatusRecruiting
StartedApril 20, 2026
Main results expectedApril 30, 2027
Study endsJuly 30, 2027
Registry record updatedNovember 6, 2026
Trial IDNCT07541196 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with chronic wounds (>3 months) and wound surface area between 2 and 20 cm²—including Wagner grade 1–2 diabetic foot ulcers, pressure injuries grade I–III, dehiscent surgical wounds, and venous or arterial ulcers—with diabetic patients having HbA1c < 9% are ideal candidates.

Probably not a fit

Patients with clinical or radiologic osteomyelitis, severe arterial insufficiency (ABI < 0.5), active malignancy or immunosuppression, pregnancy, or wounds outside the size/duration criteria are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, controlled, parallel-group trial comparing a PAW-functionalized Carbopol® 940 hydrogel applied 2–3 times weekly with standard advanced wound care in adults with chronic wounds that have failed to heal for more than three months. Participants are randomized 1:1 and treated at the Wound Clinic of Centro Médico ISSEMYM in collaboration with the Instituto Nacional de Investigaciones Nucleares, with PAW-hydrogel manufactured and quality-tested at ININ. Primary outcomes include wound area reduction by planimetry and changes in bacterial load, and safety will be monitored through local adverse events and pain reporting. The hydrogel is applied as a uniform 3–5 mm layer after cleansing, with regular follow-up visits for wound measurement and culture sampling.

Why it matters

Potential benefit: If successful, the PAW-hydrogel could speed wound closure, reduce bacterial burden, and lower the risk of infection or more invasive treatments for people with chronic wounds.

How similar studies have gone: Laboratory studies and small clinical reports of plasma-activated water and cold-plasma treatments show promising antimicrobial and healing effects, but PAW-functionalized hydrogels have limited clinical data and are relatively novel in practice.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults ≥ 18 years of age.
* Diagnosis of chronic wound (diabetic foot ulcer Wagner grade 1-2, pressure injury grade I-III, dehiscent surgical wound, venous or arterial ulcer) with duration \> 3 months.
* Wound surface area between 2 cm² and 20 cm².
* For diabetic patients: HbA1c \< 9% (stable metabolic control).
* Able and willing to provide written informed consent.

Exclusion Criteria:

* Clinical or radiological evidence of osteomyelitis (Wagner grade \> 3).
* Severe arterial insufficiency (ankle-brachial index \< 0.5).
* Use of systemic corticosteroids or immunosuppressants.
* Pregnancy or lactation.
* Known autoimmune skin disease (e.g., pemphigus, epidermolysis bullosa).
* Active malignancy or undergoing chemotherapy/radiotherapy.
* Participation in another interventional clinical trial within 30 days prior to screening.

Where it's running

  • Plasma Physics Laboratory, National Institute of Nuclear Research
    Ocoyoacac, State of Mexico, Mexico
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.